期刊文献+

甲状腺乳头状癌患者血清促甲状腺激素水平和组织促甲状腺激素受体检测的临床应用价值 被引量:19

Clinical Application Value of Serum Thyrotropin Level and Tissue Thyrotropin Receptor Detection in Patients with Thyroid Papillary Carcinoma
下载PDF
导出
摘要 目的探讨血清中促甲状腺激素(thyroid stimulating hormone,TSH)和甲状腺组织中促甲状腺激素受体(thyroid stimulating hormone recepter,TSHR)在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)中的应用价值。方法收集甲状腺乳头状癌标本55例,结节性甲状腺肿标本32例,采用化学发光法检测血清中TSH和免疫组化法检测甲状腺组织中TSHR的表达。结果PTC中血清TSH水平明显高于结节性甲状腺肿,差异具有统计学意义(χ^2=-2.163,P<0.05);且PTC中,Ⅲ/Ⅳ期患者的血清TSH水平明显高于Ⅰ/Ⅱ期,差异具有统计学意义(χ^2=-2.037,P<0.05);血清TSH的水平与患者年龄、性别、淋巴结转移与否和肿瘤大小,差异均无统计学意义(Z=-0.024~-1.262,均P>0.05)。TSHR在PTC中的表达阳性率明显低于结节性甲状腺肿,差异具有统计学意义(χ^2=4.845,P<0.05);PTC中,Ⅰ/Ⅱ期的表达阳性率高于Ⅲ/Ⅳ期,淋巴结未转移组的表达阳性率明显高于淋巴结转移组,差异具有统计学意义(Z=-3.097,-2.423,均P<0.05);TSHR的表达与患者年龄、性别和肿瘤大小,差异均无统计学意义(Z=-0.846~-1.73,均P>0.05)。结论血清TSH水平与PTC发病和TNM分期有关;TSHR的表达与PTC发病、TNM分期和淋巴结转移与否有关,两者可以作为PTC诊断和预后判断的一项参考指标。 Objective To investigate the application value of serum thyroid stimulating hormone(TSH)and thyroid tissue thyroid stimulating hormone recepter(TSHR)in papillary thyroid carcinoma(PTC).Methods 55 cases of papillary thyroid carcinoma and 32 cases of nodular goiter were collected.TSH in serum was detected by chemiluminescence method and TSHR expression in thyroid tissue was detected by immunohistochemistry.Results The serum TSH level in PTC was significantly higher than that in nodular goiter,and the difference was statistically significant(χ^2=-2.163,P<0.05).The level of serum TSH in phaseⅢ/Ⅳwas significantly higher than that in phaseⅠ/Ⅱ,and the difference was statistically significant(χ^2=-2.037,P<0.05).There was no significant difference in serum TSH level with age,gender,lymph node metastasis or tumor size(Z=-0.024~1.262,all P>0.05).The positive rate of TSHR in PTC was significantly lower than that in nodular goiter,and the difference was statistically significant(χ^2=4.845,P<0.05).The positive rate ofⅠ/Ⅱphase in PTC was significantly higher than that inⅢ/Ⅳphase,and the difference was statistically significant(Z=-3.097,P<0.05).The expression of TSHR in the non-lymphatic metastasis group was significantly higher than that in the lymphatic metastasis group,and the difference was statistically significant(Z=-2.423,P<0.05).The expression of TSHR had no significant relationship with age,sex and tumor size(Z=-0.846~-1.73,P>0.05).Conclusion Serum TSH level was related to PTC morbidity and TNM staging,the expression of TSHR was related to PTC morbidity,TNM staging and lymphatic metastasis.Both of them can be used as a reference index for PTC diagnosis and prognosis.
作者 王玲 王健 赵寅生 黄其峰 吴黎黎 WANG Ling;WANG Jian;ZHAO Yin-sheng;HUANG Qi-feng;WU Li-li(Department of Clincal Laboratory,the 901th Hospital of People’s Liberation,Hefei 230001,China;Department of Pathology,the 901th Hospital of People’s Liberation,Hefei 230001,China)
出处 《现代检验医学杂志》 CAS 2021年第1期61-64,共4页 Journal of Modern Laboratory Medicine
关键词 甲状腺乳头状癌 结节性甲状腺肿 促甲状腺激素受体 促甲状腺激素 papillary thyroid carcinoma nodular goiter thyroid stimulating hormone recepter thyroid stimulating hormone
  • 相关文献

参考文献5

二级参考文献83

  • 1Clark OH.Thyroid cancer and lymph node metastases[J].J Surg Onco1,2011,103 (6):615-618.
  • 2Kazaure HS,Roman SA,Sosa JA,et al.Aggressive variants of papillary thyroid cancer:incidence,characteristics and predictors of survival among 43,738 Patients[J].Annals of Surgical Oncology,2012,19(6):1874-1880.
  • 3Lloyd RV,Buehler D,Khanafshar E.Papillary thyroid carcinoma variants[J].Head and Neck Pathol,2011,5(1):51-56.
  • 4Gonzalez-Gonzalez R,Bologna-Molina R,Carreon-Burciaga RG,et al.Papillary thyroid carcinoma:differential diagnosis and prognostic values of its different variants.review of the literature[J].ISRN Oncol,2011:1-9.
  • 5Roman S,Sosa JA.Aggressive variants of papillary thyroid cancer[J].Curr Opin Oncol,2013,25(1):33-38.
  • 6Lino-Silva LS,Domínguez-Malagón HR,Caro-Sánchez CH,et al.Thyroid gland papillary carcinomas with " micropapillary pattern," a recently recognized poor prognostic finding:clinicopathologic and survival analysis of 7 cases[J].Hum Pathol,2012,43 (10):1596-1600.
  • 7LiVolsi VA.Papillary thyroid carcinoma:an update[J].Mod Pathol,2011,24 (2):1-9.
  • 8Koo JS,Hong S,Park CS.Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young[J].Thyroid,2009,19(11):1225-1231.
  • 9Chen CC,Chen WC,Peng SL,et al.Diffuse sclerosing variant of thyroid papillary carcinoma:Diagnostic challenges occur with Hashimoto's thyroiditis[J].J Formos Med Assoc,2013,112 (6):358-362.
  • 10McElvanna K,Stirling I,McCusker G,et al.Diffuse sclerosing variant of papillary thyroid carcinoma-a rare cause of goitre in a young patient[J].Ulster Med J,2007,76 (2):113-114.

共引文献40

同被引文献198

引证文献19

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部